Literature DB >> 17048020

[Prophylactic measures and acute treatment of migraine].

H Göbel1, A Heinze, K Heinze-Kuhn.   

Abstract

The treatment of migraine consists of the acute treatment of the migraine attack and prophylactic measures for either pharmacological or non-pharmacological management. Since the retreat of the ergotamines one can only choose between one of the well-established analgesics and one of seven triptans for the treatment of the migraine attack. Although neither a new triptan nor an innovative new application form has been introduced, the year 2006 will be remembered as the year when the first triptan (naratriptan) was released as a prescription-free over-the-counter drug and when the first sumatriptan generics were marketed in Germany. In addition to the beta-blockers metoprolol and propranolol and the calcium antagonist flunarizine two antiepileptic drugs, topiramate and valproic acid, have been rated as first-line prophylactic drugs in Germany. Due to an extensive and successful study program topiramate has been officially approved in Germany.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048020     DOI: 10.1007/s00482-006-0502-7

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  9 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  Rare missense variants in ATP1A2 in families with clustering of common forms of migraine.

Authors:  Unda Todt; Martin Dichgans; Karin Jurkat-Rott; Axel Heinze; Giovanni Zifarelli; Jan B Koenderink; Ingrid Goebel; Vera Zumbroich; Anne Stiller; Alfredo Ramirez; Thomas Friedrich; Hartmut Göbel; Christian Kubisch
Journal:  Hum Mutat       Date:  2005-10       Impact factor: 4.878

3.  Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.

Authors:  Hartmut Göbel; Axel Heinze; Gerhard Reichel; Harald Hefter; Reiner Benecke
Journal:  Pain       Date:  2006-06-05       Impact factor: 6.961

Review 4.  Non pharmaceutical treatments for migraine.

Authors:  H Göbel
Journal:  Rev Neurol (Paris)       Date:  2005-07       Impact factor: 2.607

5.  The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache.

Authors:  S D Silberstein; J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; T J Steiner
Journal:  Cephalalgia       Date:  2005-06       Impact factor: 6.292

6.  MTHFR C677T polymorphism and migraine with aura.

Authors:  Unda Todt; Jan Freudenberg; Ingrid Goebel; Christian Netzer; Axel Heinze; Katja Heinze-Kuhn; Hartmut Göbel; Christian Kubisch
Journal:  Ann Neurol       Date:  2006-11       Impact factor: 10.422

7.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

8.  Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.

Authors:  M D Ferrari; P J Goadsby; K I Roon; R B Lipton
Journal:  Cephalalgia       Date:  2002-10       Impact factor: 6.292

9.  Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.

Authors:  Mohamed Omar Tawfik; Vladimir Bryuzgin; Galina Kourteva
Journal:  Curr Med Res Opin       Date:  2004-03       Impact factor: 2.580

  9 in total
  2 in total

1.  [Development and implementation of integrated health care in pain medicine : the nationwide German headache treatment network].

Authors:  H Göbel; A Heinze; K Heinze-Kuhn; K Henkel; A Roth; H-H Rüschmann
Journal:  Schmerz       Date:  2009-12       Impact factor: 1.107

2.  Effectiveness of Vitamin B2 versus Sodium Valproate in Migraine Prophylaxis: a randomized clinical trial.

Authors:  Abolghasem Rahimdel; Ahmad Zeinali; Pouria Yazdian-Anari; Rahele Hajizadeh; Ehsan Arefnia
Journal:  Electron Physician       Date:  2015-10-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.